Showing 4851-4860 of 7172 results for "".
- Researchers Discover Anti-Aging Potential in an Invasive Weedhttps://practicaldermatology.com/news/researchers-discover-anti-aging-potential-in-an-invasive-weed/2461638/The fruit of the cocklebur plant, which grows worldwide and is often considered a noxious weed, has antioxidant and anti-inflammatory components that could make it useful as a skin protectant, according to new research
- FDA Approves Humira Biosimilar Hyrimozhttps://practicaldermatology.com/news/fda-approves-humira-biosimilar-hyrimoz/2461636/The FDA approved a citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab-adaz; Sandoz) injection, a biosimilar to Humira (adalimumab). The adalimumab citrate-free HCF (100 mg/mL) is approved to treat seven indications covered by the reference medicine, Humira, in
- Study: Atopic Asthma/Eczema Linked to Heightened Risk of Osteoarthritishttps://practicaldermatology.com/news/study-atopic-asthmaeczema-linked-to-heightened-risk-of-osteoarthritis/2461635/People with atopic diseases like asthma or eczema may be at heightened risk of osteoarthritis, according to research published online in the Annals of the Rheumatic Diseases. Drugs used to dampen d
- EON Robotic Body Contouring Device Receives Additional FDA Clearance for Back and Thighshttps://practicaldermatology.com/news/eon-robotic-body-contouring-device-receives-additional-fda-clearance-for-back-and-thighs/2461629/EON Smarter Body Contouring has received FDA clearance for the back and thighs—the third FDA clearance for EON. The device was previously FDA-cleared for clinical providers to treat patients' full abdomen and flanks. Parent company Dominion Aesthetic Technologies describe
- OliX Pharmaceuticals to Start Phase 1 Trial of Androgenic Alopecia Treatmenthttps://practicaldermatology.com/news/olix-pharmaceuticals-to-start-phase-1-trial-of-androgenic-alopecia-treatment/2461626/OliX Pharmaceuticals received regulatory approval to start Phase 1 trial of androgenic alopecia treatment in Australia. The trial is a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose Phase 1 study. The primary objective of the study is to evalu
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Burt's Bees Products Improve Redness, Pigmentation, and Reduce Acne-related PIHhttps://practicaldermatology.com/news/burts-bees-products-improve-redness-pigmentation-and-reduce-acne-related-pih/2461624/Burt’s Bees topical bakuchiol-containing sunscreen treats redness and pigmentation of photodamaged facial skin. What’s more, a cream containing Glycyrrhiza glabra (licorice root), Curcuma longa (turmeric root), and Terminalia chebula improves&n
- Take That SKs! DermBiont’s SM-020 Topical Gel Performs Well in Phase 2 Studyhttps://practicaldermatology.com/news/take-that-sks-dermbionts-sm-020-topical-gel-performs-well-in-phase-2-study/2461623/More than 80% of seborrheic keratosis (SK) lesions treated for 14 to 28 days with DermBiont’s SM-020 gel 1.0% had at least a one-point improvement in Physician’s lesion assessment (PLA) score at last visit, according to Phase 2 trial data presented at the
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t